JP6545788B2 - うつ病の治療方法 - Google Patents

うつ病の治療方法 Download PDF

Info

Publication number
JP6545788B2
JP6545788B2 JP2017507823A JP2017507823A JP6545788B2 JP 6545788 B2 JP6545788 B2 JP 6545788B2 JP 2017507823 A JP2017507823 A JP 2017507823A JP 2017507823 A JP2017507823 A JP 2017507823A JP 6545788 B2 JP6545788 B2 JP 6545788B2
Authority
JP
Japan
Prior art keywords
patient
depression
acid
esketamine
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017507823A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524719A (ja
JP2017524719A5 (https=
Inventor
リー，キンキン，エス．
ドレヴェッツ，ウェイン，シー．
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー．, ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2017524719A publication Critical patent/JP2017524719A/ja
Publication of JP2017524719A5 publication Critical patent/JP2017524719A5/ja
Application granted granted Critical
Publication of JP6545788B2 publication Critical patent/JP6545788B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Otolaryngology (AREA)
JP2017507823A 2014-08-13 2015-08-12 うつ病の治療方法 Active JP6545788B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462036896P 2014-08-13 2014-08-13
US62/036,896 2014-08-13
PCT/US2015/044830 WO2016025581A1 (en) 2014-08-13 2015-08-12 Method for the treatment of depression

Publications (3)

Publication Number Publication Date
JP2017524719A JP2017524719A (ja) 2017-08-31
JP2017524719A5 JP2017524719A5 (https=) 2018-09-20
JP6545788B2 true JP6545788B2 (ja) 2019-07-17

Family

ID=55301311

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017507823A Active JP6545788B2 (ja) 2014-08-13 2015-08-12 うつ病の治療方法

Country Status (11)

Country Link
US (1) US10098854B2 (https=)
EP (1) EP3179993B1 (https=)
JP (1) JP6545788B2 (https=)
KR (1) KR20170040800A (https=)
CN (1) CN106714789A (https=)
AU (2) AU2015301782B2 (https=)
CA (1) CA2957926A1 (https=)
IL (2) IL250490A0 (https=)
MA (1) MA40462A (https=)
MX (1) MX2017001908A (https=)
WO (1) WO2016025581A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
SI3043785T1 (sl) 2013-09-13 2022-02-28 National University Corporation Chiba University Uporaba R-ketamina in njegove soli kot farmacevtska sredstva
CA2936809A1 (en) * 2014-01-14 2015-07-23 Children's Hospital Medical Center Compositions comprising ketamine for treating an autism spectrum disorder
CN107208133A (zh) 2014-09-15 2017-09-26 詹森药业有限公司 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
MX2020006650A (es) 2017-12-22 2020-11-06 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
JP7548669B2 (ja) 2018-02-15 2024-09-10 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
AU2019262197B2 (en) 2018-05-04 2024-12-19 Perception Neuroscience, Inc. Methods of treating substance abuse
EP3628313B1 (en) * 2018-09-28 2025-02-12 Novohale Therapeutics, LLC Ketamine composition for use in a method of treatment of depression by pulmonary administration
CA3127607A1 (en) * 2019-01-23 2020-07-30 The Regents Of The University Of Michigan Pharmacogenomic decision support for modulators of the nmda, glycine, and ampa receptors
MX2021010683A (es) 2019-03-05 2021-12-10 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
WO2021262871A1 (en) * 2020-06-25 2021-12-30 Greenway Dna Inc. Methods and systems for providing a personalized treatment regimen using cannabinoid or psychedelic compounds
CN117355302A (zh) 2021-04-30 2024-01-05 思维医学股份有限公司 Lsd盐晶体形式
JP2024529727A (ja) 2021-08-19 2024-08-08 マインド メディシン， インコーポレイテッド 治療適用のためのｄ－リゼルグ酸ジエチルアミドの凍結乾燥された口腔内崩壊錠製剤

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
JPS632932A (ja) 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
DE4312016A1 (de) 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
AU758679B2 (en) 1998-07-24 2003-03-27 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
EP1103256A1 (de) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
AU2003268026A1 (en) 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20060276550A1 (en) 2005-06-03 2006-12-07 Dileep Bhagwat Topical compositions of ketamine and butamben and methods of their use
WO2007111880A2 (en) 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
US20090306137A1 (en) 2006-05-22 2009-12-10 Wolfgang Curt D Treatment for depressive disorders
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
US8710070B2 (en) 2008-03-27 2014-04-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
SI2582366T1 (sl) 2010-06-15 2016-02-29 Gruenenthal Gmbh Farmacevtska kombinacija za zdravljenje bolečine
KR102035877B1 (ko) * 2011-11-14 2019-10-23 알파시그마 에스.피.에이. 우울증이 있는 대상체를 위한 치료 양생법 선택을 위한 검정법 및 치료 방법
PE20141906A1 (es) 2012-03-12 2014-12-05 Janssen Pharmaceutica Nv Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
JP6722453B2 (ja) 2012-08-23 2020-07-15 スチュアート エル ウェグ 抗不安薬組成物、製剤および使用方法
JP6462663B2 (ja) 2013-04-12 2019-01-30 アイカーン スクール オブ メディシン アット マウント シナイ 心的外傷後ストレス障害を処置するための方法
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression

Also Published As

Publication number Publication date
CN106714789A (zh) 2017-05-24
JP2017524719A (ja) 2017-08-31
US20160045455A1 (en) 2016-02-18
EP3179993A4 (en) 2018-03-28
AU2015301782B2 (en) 2020-09-03
IL250490A0 (en) 2017-03-30
EP3179993B1 (en) 2021-01-20
MX2017001908A (es) 2017-08-08
IL279627A (en) 2021-03-01
WO2016025581A1 (en) 2016-02-18
KR20170040800A (ko) 2017-04-13
MA40462A (fr) 2017-06-21
EP3179993A1 (en) 2017-06-21
AU2020281101A1 (en) 2021-01-07
US10098854B2 (en) 2018-10-16
AU2015301782A1 (en) 2017-03-02
CA2957926A1 (en) 2016-02-18

Similar Documents

Publication Publication Date Title
JP6545788B2 (ja) うつ病の治療方法
US20230089113A1 (en) Methods For The Treatment Of Depression
JP2010070573A (ja) ストレス関連障害を含む機能的身体障害の予防および処置
JP2018515557A (ja) うつ病を治療するための方法及びキット
JP6528158B2 (ja) Ｄｒｄ２又はａｎｋｋ１のｓｎｐ遺伝子型に基づく抗精神病治療
JP2024516297A (ja) うつ病の治療のための組成物及び方法
US11998525B2 (en) Compositions and methods for the treatment of depression
JP2008518921A (ja) うつ病のための補助療法
US20250221960A1 (en) Compositions and methods for the treatment of depression
JP2007504181A (ja) セロトニン再取り込み阻害剤およびロキサピンの併用
US20250177350A1 (en) Compositions and methods for the treatment of depression
US20240238245A1 (en) Compositions and methods for the treatment of depression
KR20240132501A (ko) 우울증 치료를 위한 조성물 및 방법
JP2007504180A (ja) セロトニン再取り込み阻害剤およびアモキサピンの併用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180810

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190417

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190612

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190619

R150 Certificate of patent or registration of utility model

Ref document number: 6545788

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250